News And Notes
May 2008
in “
Trends in Urology Gynaecology & Sexual Health
”
TLDR Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
The document discussed several medical studies and developments. A study on loop diuretics in elderly men found that continuous use could double the rate of bone loss compared to non-users. A Cochrane review indicated that finasteride reduced prostate cancer risk by about 25%, though it was associated with an increase in high-grade tumors. Germany introduced the GnRH antagonist abarelix for prostate cancer, which rapidly reduced testosterone without hormonal surge. A trial on transdermal testosterone in women showed minimal benefit in sexual satisfaction, with only the 90µl dose showing a statistically significant but small increase in satisfactory sexual events. The most common side effect was hypertrichosis.
